Fulcrum Therapeutics, Inc.
NASDAQ:FULCBiotechnology
+$0.06 today
- Market cap
- $284.14M
- Beta
- 2.92
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.00
Volume 0.63M
Average 1.78M
FULC Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Fulcrum Therapeutics, Inc.NASDAQ: FULC
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $18.76M (cash outflow) rose 22.9% year over year, ahead of the -945.1% change in trailing-twelve-month free cash flow. Sequentially, it rose 10.6% from the prior quarter. Over 3 fiscal years it compounded at -15.2% a year.
Context
- Free cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +22.9% holds above the trailing-twelve-month pace of -945.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (60.38M) USD
- Year-over-year change
- -2319.0%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (60.38M) | -2319.0% |
| FY2024 | 2024-12-31 | (2.5M) | +97.3% |
| FY2023 | 2023-12-31 | (91.47M) | +7.6% |
| FY2022 | 2022-12-31 | (99.01M) | -23.5% |
| FY2021 | 2021-12-31 | (80.19M) | — |
Free Cash Flow vs competitors
How FULC compares with its peers on the latest reported figures
- FULC's LTM Mar 2026 free cash flow of $63.88M is the 6th largest of the 10 companies compared; the peer median is $82.61M.
- Its year-over-year change of -945.1% is the lowest of 10, against a peer median of -1.4%.
- Over three fiscal years its annual growth of -15.2% compares with a peer median of +11.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $229.01M | +25.5% | +34.0% | 360.7% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $193.4M | -3.0% | +21.4% | — |
| LTM Mar 2026 | $114.59M | -16.2% | +0.6% | 144.7% | |
| LTM Mar 2026 | $94.78M | -33.7% | +10.3% | 958.1% | |
| LTM Mar 2026 | $82.61M | +15.9% | +12.5% | — | |
| LTM Mar 2026 | $63.88M | -945.1% | -15.2% | — | |
| LTM Mar 2026 | $59.58M | +14.7% | -4.0% | 1334.3% | |
| LTM Mar 2026 | $53.29M | +20.5% | +12.7% | — | |
| LTM Mar 2026 | $38.8M | -77.0% | -9.0% | 55.7% | |
| LTM Mar 2026 | $22.3M | -1.4% | — | 150.9% | |
| Peer median (excluding FULC) | $82.61M | -1.4% | +11.4% | 255.8% | |
Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Depreciation & Amortization | 2.52M | 2.41M | 2.17M | 1.59M | 1.39M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.07M | 13.35M | 14.8M | 14.55M | 12.47M |
| Change in Working Capital | (11.89M) | (3.09M) | (4.61M) | (4.25M) | 3.91M |
| Accounts Receivables | (500K) | 2.5M | (308K) | (1.56M) | 2.1M |
| Inventory | 1.25M | 0 | 0 | 0 | 0 |
| Accounts Payables | 973K | (1.18M) | (853K) | (1.59M) | 428K |
| Other Working Capital | (13.61M) | (4.42M) | (3.45M) | (1.1M) | 1.39M |
| Other Non-Cash Items | 673K | 152K | (5.99M) | (4.39M) | (2.95M) |
| Operating Cash Flow | (78.48M) | (97.05M) | (90.97M) | (2.22M) | (60.07M) |
| Capital Expenditures | (1.71M) | (1.96M) | (508K) | (278K) | (314K) |
| Acquisitions (Net) | 127.96M | (14.38M) | 0 | 0 | 0 |
| Purchases of Investments | (216.23M) | (151.15M) | (194.89M) | (178.59M) | (180.22M) |
| Sales of Investments | 88.28M | 165.53M | 158.71M | 211.1M | 211.25M |
| Other Investing Activities | (127.96M) | 14.38M | 0 | 0 | 0 |
| Investing Cash Flow | (129.67M) | 12.41M | (36.69M) | 32.23M | 30.72M |
| Debt Repayment | (18K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 182.86M | 80.8M | 117.35M | 2.75M | 168.67M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.67M | 3.52M | 777K | 0 | 0 |
| Financing Cash Flow | 186.51M | 84.32M | 118.12M | 2.75M | 168.67M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (21.64M) | (314K) | (9.54M) | 32.76M | 139.32M |
| Free Cash Flow | (80.19M) | (99.01M) | (91.47M) | (2.5M) | (60.38M) |
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
Intrinsic Alpha fair value
Locked
Current Price
$3.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.